The FDA has approved Aqneursa (levacetylleucine) to treat neurological symptoms of Niemann-Pick disease type C (NPC) in adults and children over 15 kg. NPC is a rare genetic disorder causing lipid buildup in cells, particularly affecting the brain. Aqneursa offers new hope by targeting these neurological symptoms, marking a significant step forward for patients with this challenging condition.